<DOC>
	<DOC>NCT00783081</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.</brief_summary>
	<brief_title>Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication</brief_title>
	<detailed_description />
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Stable claudication symptoms Lower extremity amputation Signs or symptoms of critical leg ischemia (CLI) Uncontrolled hypertension Tachycardia Poorly controlled diabetes Hypercholesterolemia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Intermittent Claudication</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
</DOC>